US › Healthcare

Aligos Therapeutics Inc (ALGS)

US · Healthcare · Biotechnology

$5.17+2.38%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$27.8M

Revenue YoY

+2778.5%

Net profit

$-1.5M

EPS

$-0.14

EPS estimate

$-1.41

Net margin

-5.4%

EPS came in at -0.14 against a street estimate of -1.41 — a beat of 90.1%.

Key statistics

Market cap

$32.6M

Forward P/E

0.0

P/B

1.03

Book value

$5.11

EPS (TTM)

$-7.71

52-week high

$13.69

52-week low

$3.98

50-day MA

$5.91

200-day MA

$7.08

Beta

2.33

Analyst view

Analysts rate Aligos Therapeutics Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $53.43.

Shareholding

Insiders

10.64%

Institutions

45.65%

Largest institutional holders

Fund	Stake
Deep Track Capital, LP	7.11%
Alyeska Investment Group, L.P.	6.60%
Sio Capital Management, LLC	5.24%
Marshall Wace Asset Management Ltd	4.28%
Bank of America Corp	3.68%
Vanguard Capital Management, LLC	2.85%
Woodline Partners LP	2.84%
SummitTX Capital, L.P	2.38%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aligos Therapeutics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.